Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of 23.13% is in line with its 5-year average of 22.44%, near the high end of its 5-year range (16.44%–23.77%).
As of the fiscal period ended Tuesday, June 30, 2026. 1.15% below its 12-month average of 23.40%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q4 FY2026 (2026-06-30): 23.13%.
RETURN ON EQUITY (ROE)
23.13%
RETURN ON EQUITY (ROE) AVG TTM
23.40%
RETURN ON EQUITY (ROE) AVG 3Y
22.35%
RETURN ON EQUITY (ROE) AVG 5Y
22.44%
RETURN ON EQUITY (ROE) AVG 10Y
20.63%
RETURN ON EQUITY (ROE) AVG 15Y
20.04%
RETURN ON EQUITY (ROE) AVG 20Y
17.95%
CURRENT VS TTM AVG
-1.15%
CURRENT VS 3Y AVG
+3.52%
CURRENT VS 5Y AVG
+3.07%
CURRENT VS 10Y AVG
+12.13%
CURRENT VS 15Y AVG
+15.41%
CURRENT VS 20Y AVG
+28.88%
SECTOR MEDIAN · HEALTHCARE
13.01%
median of 84 covered companies
CURRENT VS SECTOR MEDIAN
+77.80%
vs the sector median at left
ResMed Inc.
Market Cap
$32.30B
Return on Equity (ROE)
23.13%
TTM Avg
23.40%
3Y Avg
22.35%
5Y Avg
22.44%
Market Cap
$32.86B
Return on Equity (ROE)
38.14%
TTM Avg
28.93%
3Y Avg
25.01%
5Y Avg
22.95%
Market Cap
$33.66B
Return on Equity (ROE)
4.43%
TTM Avg
8.42%
3Y Avg
11.86%
5Y Avg
16.52%
Market Cap
$30.59B
Return on Equity (ROE)
-22.60%
TTM Avg
-10.46%
3Y Avg
-1.37%
5Y Avg
1.10%
Market Cap
$30.46B
Return on Equity (ROE)
7062.40%
TTM Avg
-2178.82%
3Y Avg
-341.14%
5Y Avg
-117.12%
Market Cap
$34.28B
Return on Equity (ROE)
59.67%
TTM Avg
-187.43%
3Y Avg
134.89%
5Y Avg
51.69%
Market Cap
$30.12B
Return on Equity (ROE)
14.51%
TTM Avg
21.84%
3Y Avg
21.53%
5Y Avg
32.27%
Market Cap
$29.67B
Return on Equity (ROE)
83.10%
TTM Avg
66.19%
3Y Avg
56.82%
5Y Avg
52.60%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| ResMed Inc. (RMD) | $32.30B | 23.13% | 23.40% | 22.35% | 22.44% |
| DexCom, Inc. (DXCM)vs › | $32.86B | 38.14% | 28.93% | 25.01% | 22.95% |
| Alcon Inc. (ALC)vs › | $31.41B | 2.96% | 4.58% | 3.90% | 2.45% |
| Biogen Inc. (BIIB)vs › | $33.66B | 4.43% | 8.42% | 11.86% | 16.52% |
| Centene Corp. (CNC)vs › | $30.59B | -22.60% | -10.46% | -1.37% | 1.10% |
| Mettler-Toledo International Inc. (MTD)vs › | $30.46B | 7062.40% | -2178.82% | -341.14% | -117.12% |
| Alnylam Pharmaceuticals, Inc. (ALNY)vs › | $34.28B | 59.67% | -187.43% | 134.89% | 51.69% |
| GE HealthCare Technologies Inc. (GEHC)vs › | $30.12B | 14.51% | 21.84% | 21.53% | 32.27% |
| Zoetis Inc. (ZTS)vs › | $29.67B | 83.10% | 66.19% | 56.82% | 52.60% |
| Medline Inc. (MDLN)vs › | $29.50B | 5.97% | 9.02% | 4.86% | 4.86% |
ROE
23.1%
ROA
17.0%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | 23.13% |
| 2026-03-31 | 23.41% |
| 2025-12-31 | 23.51% |
| 2025-09-30 | 23.49% |
| 2025-06-30 | 23.47% |
| 2025-03-31 | 23.68% |
| 2024-12-31 | 23.77% |
| 2024-09-30 | 21.42% |
| 2024-06-30 | 20.99% |
| 2024-03-31 | 20.70% |
| 2023-12-31 | 19.87% |
| 2023-09-30 | 21.33% |
| 2023-06-30 | 21.73% |
| 2023-03-31 | 21.94% |
| 2022-12-31 | 21.65% |
| 2022-09-30 | 22.90% |
| 2022-06-30 | 23.19% |
| 2022-03-31 | 23.77% |
| 2021-12-31 | 16.59% |
| 2021-09-30 | 16.51% |
| 2021-06-30 | 16.44% |
| 2021-03-31 | 16.88% |
| 2020-12-31 | 24.39% |
| 2020-09-30 | 25.38% |
| 2020-06-30 | 24.90% |
| 2020-03-31 | 22.72% |
| 2019-12-31 | 20.15% |
| 2019-09-30 | 19.79% |
| 2019-06-30 | 19.52% |
| 2019-03-31 | 22.05% |
| 2018-12-31 | 23.02% |
| 2018-09-30 | 17.64% |
| 2018-06-30 | 15.33% |
| 2018-03-31 | 14.87% |
| 2017-12-31 | 14.12% |
| 2017-09-30 | 17.19% |
| 2017-06-30 | 17.46% |
| 2017-03-31 | 17.46% |
| 2016-12-31 | 19.11% |
| 2016-09-30 | 19.50% |
| 2016-06-30 | 20.79% |
| 2016-03-31 | 21.32% |
| 2015-12-31 | 23.42% |
| 2015-09-30 | 24.13% |
| 2015-06-30 | 22.23% |
| 2015-03-31 | 22.99% |
| 2014-12-31 | 22.17% |
| 2014-09-30 | 21.03% |
| 2014-06-30 | 19.64% |
| 2014-03-31 | 19.55% |
| 2013-12-31 | 19.86% |
| 2013-09-30 | 18.72% |
| 2013-06-30 | 19.07% |
| 2013-03-31 | 17.59% |
| 2012-12-31 | 16.60% |
| 2012-09-30 | 16.22% |
| 2012-06-30 | 15.85% |
| 2012-03-31 | 14.70% |
| 2011-12-31 | 14.43% |
| 2011-09-30 | 14.25% |
| 2011-06-30 | 13.11% |
| 2011-03-31 | 13.33% |
| 2010-12-31 | 13.48% |
| 2010-09-30 | 13.86% |
| 2010-06-30 | 14.76% |
| 2010-03-31 | 13.68% |
| 2009-12-31 | 13.73% |
| 2009-09-30 | 13.34% |
| 2009-06-30 | 13.13% |
| 2009-03-31 | 13.44% |
| 2008-12-31 | 12.58% |
| 2008-09-30 | 11.72% |
| 2008-06-30 | 10.20% |
| 2008-03-31 | 10.13% |
| 2007-12-31 | 6.24% |
| 2007-09-30 | 6.66% |
| 2007-06-30 | 7.12% |
| 2007-03-31 | 7.07% |
| 2006-12-31 | 12.16% |
| 2006-09-30 | 12.54% |
| 2006-06-30 | 11.95% |
| 2006-03-31 | 11.97% |
| 2005-12-31 | 13.75% |
| 2005-09-30 | 13.32% |
| 2005-06-30 | 13.67% |
| 2005-03-31 | 14.02% |
| 2004-12-31 | 14.56% |
| 2004-09-30 | 15.59% |
| 2004-06-30 | 15.85% |
| 2004-03-31 | 15.60% |
| 2003-12-31 | 15.68% |
| 2003-09-30 | 15.55% |
| 2003-06-30 | 15.96% |
